MicroRNA-596 acts as a tumor suppressor in gastric cancer and is upregulated by promotor demethylation

Table 1 Sequences of primers for quantitative real-time PCR

Name	Sequence (5'-3')
Primers used for mRNA detection
miR-596 (forward)	AAGCCTGCCCGGCTCCT
miR-596 (reverse)	GCTGTCAACGATACGCTACGT
miR-596 (RT)	(GCTGTCAACGATACGCTACGTAACGGCATGACA; GTGTTTTTTTTTTTTTTTTTTTTTTTTC)
U6 (forward)	CGCTTCGGCAGCACATATAC
U6 (reverse)	TTCACGAATTTGCGTG TCAT
U6 (RT)	(GCTGTCAACGATACGCTACGTAACGGCATGACAG; TGTTTTTTTTTTTTTTTTTTTTTTTTG)
PRDX1 (forward)	AAGAAACTCAACTGCCAAGTG
PRDX1 (reverse)	CAGCCTTTAAGACCCCATAAT
GAPDH (forward)	CGGATTTGGTCGTATTGGG
GAPDH (reverse)	CTGGAAGATGGTGATGGGATT

PRDX1: Peroxiredoxin 1; MiR-596: MicroRNA-596; GAPDH: Glyceraldehyde phosphate dehydrogenase.

Table 2 Correlation between microRNA-596 expression and clinicopathological variables of gastric cancer

Variable	No. of Patients	Low expression	High expression	P-value
Age (yr)				0.667
< 60	18	14	4
≥ 60	37	32	5
Gender				1.000
Male	36	30	6
Female	19	16	3
Size (cm)				0.227
< 5	18	13	5
≥ 5	37	33	4
Tumor differentiation				0.043a
Well/moderate	23	16	7
Poor	32	30	2
Tumor location				0.827
Upper	5	4	1
Middle	12	11	1
Lower	38	31	7
Borrmann type				0.545
I + II	6	4	2
III + V	49	42	7
TNM stage				0.031a
I + II	22	15	7
III + IV	33	31	2
Lymph node metastasis				0.239
No	13	9	4
Yes	42	37	5

^aP < 0.05.